Humacyte, Inc.

General ticker "HUMA" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $607.8M (TTM average)

Humacyte, Inc. follows the US Stock Market performance with the rate: 3.0%.

Estimated limits based on current volatility of 3.4%: low 1.53$, high 1.71$

Factors to consider:

  • Current price 20.5% below estimated low
  • Earnings for 12 months up through Q4 are below our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [1.87$, 4.84$]
  • 2024-12-30 to 2025-12-30 estimated range: [1.82$, 4.71$]

Financial Metrics affecting the HUMA estimates:

  • Negative: Non-GAAP EPS, $ of -0.93 <= 0.04
  • Negative: negative Operating income
  • Negative: Operating cash flow per share per price, % of -20.30 <= 1.79
  • Negative: Shareholder equity ratio, % of 10.56 <= 22.52
  • Negative: negative Industry operating income (median)
  • Negative: negative Net income
  • Positive: Inventory ratio change, % of -1.94 <= -1.01
  • Negative: Industry operating cash flow per share per price (median), % of -24.70 <= 2.82

Similar symbols

Short-term HUMA quotes

2025-03-102025-03-112025-03-122025-03-132025-03-142025-03-172025-03-182025-03-192025-03-202025-03-212025-03-242025-03-252025-03-262025-03-272025-03-282025-03-312025-04-012025-04-022025-04-032025-04-042025-04-072025-04-082025-04-092025-04-102025-04-112025-04-142025-04-152025-04-162025-04-172025-04-211.522.53
Price $

Long-term HUMA plot with estimates

12345678910Jul 2023Jan 2024Jul 2024Jan 2025Jul 2025−0.3−0.2−0.10
HUMAS&P500Health CareNon-GAAP EPS EstimateNon-GAAP EPS ActualPrice $Non-GAAP EPS $

Financial data

YTD 2021-12-31 2022-12-31 2023-12-31
Operating Revenue $1.26MM $1.56MM $0.00MM
Operating Expenses $82.47MM $86.14MM $100.05MM
Operating Income $-81.21MM $-84.58MM $-100.05MM
Non-Operating Income $54.73MM $72.61MM $-10.73MM
Interest Expense $4.35MM $6.20MM $6.60MM
R&D Expense $61.34MM $63.26MM $76.55MM
Income(Loss) $-26.48MM $-11.96MM $-110.78MM
Profit(Loss)* $37.54MM $64.22MM $-110.78MM
Stockholders Equity $122.17MM $116.93MM $13.55MM
Inventory $0.00MM $0.03MM $0.00MM
Assets $286.53MM $204.30MM $128.22MM
Operating Cash Flow $-81.19MM $-71.13MM $-73.31MM
Capital expenditure $0.22MM $1.05MM $2.28MM
Investing Cash Flow $-8.22MM $4.84MM $-0.17MM
Financing Cash Flow $266.98MM $-1.45MM $4.51MM
Earnings Per Share** $0.94 $0.62 $-1.07

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.